Table 4.
Summary of the usage and efficacy of nystatin
| Risk factor | Formulation | Dose | Frequency (times/day) |
Duration (days) |
Clinical cure rate (%) |
Mycological cure rate (%) |
|---|---|---|---|---|---|---|
| Denture | Suspension | 100,000 IU | 4 | 15 | 53 | – |
| Pastille | 200,000/400,000 IU | 5 | 14 | 28.6/14.3 | 57.1/71.4 | |
| Pastille | 500,000 IU | 4 | 30 | 76.9 | 40 | |
| Young age (in infants and children) | Suspension | 100,000–400,000 IU | 4 | 10–14 | 28.6–54.1 | 5.6–11 |
| HIV/AIDS | Suspension | 100,000–500,000 IU | 3–4 | 14 | 9–63.5 | 6–13 |
| Cancer | Suspension + pastille | 1,000,000+100,000 IU | 3 | 10–12 | 87.5 | 66 |
| Multiple | Suspension | 100,000 IU | 4 | 21 | 16.7 | – |